Displaying drugs 10776 - 10800 of 11741 in total
GFT14
GFT14 is a new class of medicaction for treatment of cardiometabolic disease. GFT14 aims to target mixed dyslipidemia of type IIb (high levels of triglycerides and LDL-C) as one of the major indications of cardiometabolic disease.
GFT14 is destined to improve the condition of patients at risk from cardiovascular disease...
Investigational
Matched Description: … GFT14 is a new class of medicaction for treatment of cardiometabolic disease. ... GFT14 is destined to improve the condition of patients at risk from cardiovascular disease by a simultaneous …
GMX1777
GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic activity. In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a carbonate ester bond. Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa...
Investigational
Matched Description: … GMX1777 is a water-soluble prodrug of the cyanoguanidine compound GMX1778 with potential antineoplastic ... In vivo, apoptosis inducer GMX1777 is rapidly converted into GMX1778 through hydrolytic cleavage of a …
Rupintrivir
Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV) infections. Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells. It is designed to combat colds caused by rhinovirus.
Investigational
Matched Description: … Rupintrivir is a rhinovirus 3C protease inhibitor in development for use against human rhinoviral (HRV ... Rupintrivir was active against all 48 HRV serotypes tested in a cell protection assay in H1-HeLa cells …
INGN 225
INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53. INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer.
Investigational
Matched Description: … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector …
(4R)-limonene
Limonene is common in cosmetic products. As the main odor constituent of citrus (plant family Rutaceae), D-limonene is used in food manufacturing and some medicines, e.g. as a flavoring to mask the bitter taste of alkaloids, and as a fragrant in perfumery.
Investigational
Matched Description: … flavoring to mask the bitter taste of alkaloids, and as a fragrant in perfumery. ... citrus (plant family Rutaceae), D-limonene is used in food manufacturing and some medicines, e.g. as a …
Methylthioinosine
An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
Experimental
Matched Description: … An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position. …
IPH 2101
IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia.
Investigational
Matched Description: … IPH-2101 (NN-1975), a fully human monoclonal antibody developed for patients with acute myeloid leukemia …
MK-0482
MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT) 3.
Investigational
Matched Description: … MK-0482 is a novel humanized IgG4 monoclonal antibody targeting the immunoglobulin-like transcript (ILT …
KF-0210
KF-0210 is a small molecule developed by Keythera Pharmaceuticals. It is being investigated for cancers.
Investigational
Matched Description: … KF-0210 is a small molecule developed by Keythera Pharmaceuticals. …
PLG-0206
PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections.
Investigational
Matched Description: … PLG-0206 is a peptide antibiotic under investigation for the treatment of periprosthetic joint infections …
EP-2104R
EP-2104R is an imaging pharmaceutical under development for the detection of blood clots. It is the first targeted high-resolution technique designed to visualize blood clots directly. It is being developed by EPIX Pharmaceuticals, Inc.
Investigational
OPC-28326
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive …
Eldecalcitol
Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
Investigational
Matched Description: … Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol …
Norclozapine
ACP-104, or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a novel, stand-alone therapy for schizophrenia. It combines an atypical antipsychotic efficacy profile with the added potential benefit of enhanced cognition, thereby addressing one of the major challenges in treating schizophrenia today.
Investigational
Matched Description: … or N-desmethylclozapine, is the major metabolite of clozapine, and is being developed by ACADIA as a …
Filaminast
Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). As such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Experimental
Matched Description: … Filaminast is a phosphodiesterase 4 inhibitor (PDE4 inhibitor). …
Porfiromycin
Porfiromycin is a substance that is being studied in the treatment of cancer. It belongs to the family of drugs called anticancer antibiotics.
Investigational
Matched Description: … Porfiromycin is a substance that is being studied in the treatment of cancer. …
Diridavumab
Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of Diridavumab in Japanese Healthy Participants).
Investigational
Matched Description: … Cr6261 is under investigation in clinical trial NCT02016066 (A Study to Assess the Safety, Pharmacokinetics …
Swertia japonica whole flowering
Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Swertia japonica whole flowering is a plant/plant extract used in some OTC (over-the-counter) products …
Bixalomer
Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).
Investigational
Matched Description: … Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 …
Orilanolimab
Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Investigational
Matched Description: … Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects …
Ro 24-7429
Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With Hiv-related Kaposi's Sarcoma).
Investigational
Matched Description: … Ro 24-7429 is under investigation in clinical trial NCT00002314 (A Study of Ro 24-7429 in Patients With …
HIV Integrase Inhibitor
HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose Study of BMS-707035 in HIV-1 Infected Subjects).
Investigational
Matched Description: … HIV Integrase Inhibitor is under investigation in clinical trial NCT00397566 (A Multiple Ascending Dose …
Displaying drugs 10776 - 10800 of 11741 in total